Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).
Identifieur interne : 002845 ( Main/Exploration ); précédent : 002844; suivant : 002846Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).
Auteurs : Anil Kumar ; Pawan SachanSource :
- Tropical biomedicine [ 0127-5720 ] ; 2014.
Descripteurs français
- KwdFr :
- Albendazole (usage thérapeutique), Diéthylcarbamazine (usage thérapeutique), Filaricides (usage thérapeutique), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Inde (épidémiologie), Résultat thérapeutique, Traitement médicamenteux (), Utilisation médicament.
- MESH :
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Diéthylcarbamazine, Filaricides.
- épidémiologie : Filariose lymphatique, Inde.
- Humains, Résultat thérapeutique, Traitement médicamenteux, Utilisation médicament.
- Wicri :
- geographic : Inde.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides.
- geographic , epidemiology : India.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- methods : Drug Therapy.
- Drug Utilization, Humans, Treatment Outcome.
Abstract
Lymphatic filariasis is still endemic in many parts of India. The main strategy to implement mass drug administration with DEC and albendazole was added in 2006 to ensure increased impact on the microfilaria (mf) rate in the community. However, the effective coverage remained low in the community leading to lower than desired impact on the parasite population in human. This paper presents the dynamics of participation in annual repeated rounds of mass drug administration in some villages of Kanpur Nagar district in Uttar Pradesh and its impact over the infection rate. It is revealed that after 6 annual rounds of MDA, mf rate could only be reduced by 17.3% in population subgroups who participated only once in comparison to 88% in those who participated in 6 or all annual rounds.
PubMed: 25134891
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001380
- to stream PubMed, to step Curation: 001380
- to stream PubMed, to step Checkpoint: 001380
- to stream Ncbi, to step Merge: 006994
- to stream Ncbi, to step Curation: 006994
- to stream Ncbi, to step Checkpoint: 006994
- to stream Main, to step Merge: 002849
- to stream Main, to step Curation: 002845
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).</title><author><name sortKey="Kumar, Anil" sort="Kumar, Anil" uniqKey="Kumar A" first="Anil" last="Kumar">Anil Kumar</name><affiliation><nlm:affiliation>National JALMA Institute for Leprosy & Other Mycobacterial Disease (ICMR), Agra.</nlm:affiliation><wicri:noCountry code="subField">Agra</wicri:noCountry></affiliation></author><author><name sortKey="Sachan, Pawan" sort="Sachan, Pawan" uniqKey="Sachan P" first="Pawan" last="Sachan">Pawan Sachan</name><affiliation><nlm:affiliation>National JALMA Institute for Leprosy & Other Mycobacterial Disease (ICMR), Agra.</nlm:affiliation><wicri:noCountry code="subField">Agra</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25134891</idno><idno type="pmid">25134891</idno><idno type="wicri:Area/PubMed/Corpus">001380</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001380</idno><idno type="wicri:Area/PubMed/Curation">001380</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001380</idno><idno type="wicri:Area/PubMed/Checkpoint">001380</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001380</idno><idno type="wicri:Area/Ncbi/Merge">006994</idno><idno type="wicri:Area/Ncbi/Curation">006994</idno><idno type="wicri:Area/Ncbi/Checkpoint">006994</idno><idno type="wicri:doubleKey">0127-5720:2014:Kumar A:measuring:impact:on</idno><idno type="wicri:Area/Main/Merge">002849</idno><idno type="wicri:Area/Main/Curation">002845</idno><idno type="wicri:Area/Main/Exploration">002845</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).</title><author><name sortKey="Kumar, Anil" sort="Kumar, Anil" uniqKey="Kumar A" first="Anil" last="Kumar">Anil Kumar</name><affiliation><nlm:affiliation>National JALMA Institute for Leprosy & Other Mycobacterial Disease (ICMR), Agra.</nlm:affiliation><wicri:noCountry code="subField">Agra</wicri:noCountry></affiliation></author><author><name sortKey="Sachan, Pawan" sort="Sachan, Pawan" uniqKey="Sachan P" first="Pawan" last="Sachan">Pawan Sachan</name><affiliation><nlm:affiliation>National JALMA Institute for Leprosy & Other Mycobacterial Disease (ICMR), Agra.</nlm:affiliation><wicri:noCountry code="subField">Agra</wicri:noCountry></affiliation></author></analytic><series><title level="j">Tropical biomedicine</title><idno type="ISSN">0127-5720</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (therapeutic use)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy (methods)</term><term>Drug Utilization</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>India (epidemiology)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (usage thérapeutique)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Inde (épidémiologie)</term><term>Résultat thérapeutique</term><term>Traitement médicamenteux ()</term><term>Utilisation médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Inde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Utilization</term><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Résultat thérapeutique</term><term>Traitement médicamenteux</term><term>Utilisation médicament</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis is still endemic in many parts of India. The main strategy to implement mass drug administration with DEC and albendazole was added in 2006 to ensure increased impact on the microfilaria (mf) rate in the community. However, the effective coverage remained low in the community leading to lower than desired impact on the parasite population in human. This paper presents the dynamics of participation in annual repeated rounds of mass drug administration in some villages of Kanpur Nagar district in Uttar Pradesh and its impact over the infection rate. It is revealed that after 6 annual rounds of MDA, mf rate could only be reduced by 17.3% in population subgroups who participated only once in comparison to 88% in those who participated in 6 or all annual rounds.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Kumar, Anil" sort="Kumar, Anil" uniqKey="Kumar A" first="Anil" last="Kumar">Anil Kumar</name><name sortKey="Sachan, Pawan" sort="Sachan, Pawan" uniqKey="Sachan P" first="Pawan" last="Sachan">Pawan Sachan</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002845 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002845 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25134891
|texte= Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25134891" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |